HbA1c rose to 58 mmol/mol a | HbA1c increased 10 mmol/mol b | Change of T2DM drugs c | Combination of all definitions | |||||
---|---|---|---|---|---|---|---|---|
HR | 95%CI | HR | 95%CI | HR | 95%CI | HR | 95%CI | |
Crude model | ||||||||
Using GnRH, n (%) | ||||||||
No | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. |
Yes | 1.60 | (1.37–1.87) | 1.77 | (1.53–2.04) | 1.14 | (0.85–1.53) | 1.56 | (1.37–1.78) |
PCa risk category | ||||||||
Low risk | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. |
Intermediate risk | 1.12 | (0.98–1.29) | 1.00 | (0.87–1.15) | 0.97 | (0.76–1.23) | 0.99 | (0.88–1.12) |
High risk | 1.08 | (0.90–1.29) | 1.11 | (0.94–1.30) | 0.77 | (0.56–1.07) | 1.05 | (0.91–1.21) |
Regional metastases | 1.35 | (0.92–1.97) | 1.38 | (0.96–1.98) | 0.84 | (0.39–1.80) | 1.33 | (0.97–1.82) |
Distance metastases | 1.31 | (0.80–2.13) | 1.32 | (0.84–2.06) | 1.04 | (0.46–2.36) | 1.11 | (0.75–1.65) |
Missing data | 0.63 | (0.39–1.02) | 0.83 | (0.57–1.22) | 0.66 | (0.29–1.49) | 0.81 | (0.59–1.12) |
Adjusted model d | ||||||||
Using GnRH, n (%) | ||||||||
No | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. |
Yes | 1.56 | (1.33–1.83) | 1.78 | (1.54–2.06) | 1.21 | (0.89–1.63) | 1.58 | (1.39–1.80) |
PCa risk category | ||||||||
Low risk | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. | 1.00 | ref. |
Intermediate risk | 1.08 | (0.94–1.26) | 0.99 | (0.86–1.13) | 1.00 | (0.78–1.28) | 0.99 | (0.88–1.11) |
High risk | 0.99 | (0.83–1.20) | 1.06 | (0.90–1.26) | 0.83 | (0.60–1.16) | 1.02 | (0.88–1.18) |
Regional metastasises | 1.28 | (0.87–1.87) | 1.38 | (0.96–1.98) | 0.86 | (0.40–1.85) | 1.34 | (0.97–1.83) |
Distance metastasises | 1.25 | (0.77–2.04) | 1.25 | (0.80–1.97) | 1.12 | (0.49–2.55) | 1.08 | (0.72–1.62) |
Missing data | 0.56 | (0.34–0.92) | 0.81 | (0.55–1.19) | 0.63 | (0.27–1.43) | 0.78 | (0.57–1.09) |